Expertise in
18
conditions

Keisuke Tomii

Kobe, JP 
Expertise in
18
conditions
Kobe, JP 

Overview

Keisuke Tomii practices practicing medicine in Kobe, Japan.

Mr. Tomii is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pneumonia, and Pulmonary Alveolar Proteinosis.

He is actively involved in clinical research, co-authoring 227 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Kobe, 6500047, Japan
Other Locations
Hongo, 1130033, Japan
Sayama, Japan
Osaka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Japanese Idiopathic Interstitial Pneumonias Registry
Japanese Idiopathic Interstitial Pneumonias Registry
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
View 3 Less Clinical Trials

227 Total Publications

Expanding roles of high-flow nasal cannula beyond acute care: Home use, rehabilitation, and palliative care.
Expanding roles of high-flow nasal cannula beyond acute care: Home use, rehabilitation, and palliative care.
Journal: Respiratory investigation
Published: April 14, 2026

Frequently Asked Questions about Keisuke Tomii

Is Keisuke Tomii a top-rated expert for Interstitial Lung Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Keisuke Tomii is classified as an Elite expert for Interstitial Lung Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Keisuke Tomii participate in research or clinical trials?

Yes. Keisuke Tomii has published 227 articles and abstracts on conditions like Interstitial Lung Disease. You can view a list of Keisuke Tomii's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tomii's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile